ResMed (RMD) Tops Q3 EPS by 9c
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $217.45 -0.43%
EPS Growth %: +13.7%
Financial Fact:
Selling, general and administrative: 128.85M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: +13.7%
Financial Fact:
Selling, general and administrative: 128.85M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q3 EPS of $1.68, $0.09 better than the analyst estimate of $1.59. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.05 billion.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- Akari Therapeutics adds oncology expert Patricia LoRusso to advisory board
- TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
